Results 31 to 40 of about 325,639 (307)
A human lung tumor microenvironment interactome identifies clinically relevant cell-type cross-talk. [PDF]
, 2020 BackgroundTumors comprise a complex microenvironment of interacting malignant and stromal cell types. Much of our understanding of the tumor microenvironment comes from in vitro studies isolating the interactions between malignant cells and a single ...
Azizi, Armon +19 more
core +4 more sources
The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: A systematic review and meta-analysis [PDF]
, 2019 Background The brain is a common site for metastasis in non-small-cell lung cancer (NSCLC). This study was designed to evaluate the relationship between the mutational of the epidermal growth factor receptor (EGFR) and overall survival (OS) in NSCLC ...
Han, Yunan +11 more
core +2 more sources
Cancer Management and Research, 2022 Xiuming Huang,* Mingfang Huang,* Minbiao Chen, Xianshan Chen Department of Thoracic Surgery, Hainan General Hospital, Haikou, Hainan, 570311, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xianshan ...
Huang X, Huang M, Chen M, Chen X
doaj
Open Medicine, 2021 Non-small cell lung cancer (NSCLC) is a malignant tumor with the highest mortality rate in our country. It has been found in many studies that microRNA-4521 (miR-4521) is abnormally expressed and plays a role in clear cell renal cell carcinoma and other ...
Sun Butong +4 more
doaj +1 more source
Cancers, 2023 Non-small cell lung cancer (NSCLC) is still one of the leading causes of death worldwide. This is mostly because the majority of lung cancers are discovered in advanced stages. In the era of conventional chemotherapy, the prognosis of advanced NSCLC was grim. Important results have been reported in thoracic oncology since the discovery of new molecular
Cannone, Giorgio +7 more
openaire +3 more sources
Clinical Significance of miR-183-3p and miR-182-5p in NSCLC and Their Correlation
Cancer Management and Research, 2021 Tianxiang Zhang,1 Wei Li,2 Meng Gu,1 Ziyu Wang,1 Shijie Zhou,2 Xuefeng Hao,1 Weiying Li,1 Shaofa Xu1 1Department of Cellular and Molecular Biology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research ...
Zhang T +7 more
doaj
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis [PDF]
, 2018 The research leading to these results received funding from the Obra Social “la Caixa” (to ME), the Cellex Foundation (to ME), the European Union's Horizon 2020 research and innovation programme under grant agreement No 727264 Epipharm (to ME), the 2015 ...
Calleja Cervantes, M. E. +4 more
core +1 more source
Исследования и практика в медицине, 2021 Currently, lung cancer is a global problem and public health issue in the world. Chemoradiotherapy remains the optimal method in the treatment of patients with unresectable non-small cell lung cancer (NSCLC).
E. I. Smolenov +5 more
doaj +1 more source
Immunotherapeutic Advances for NSCLC
Biologics: Targets and Therapy, 2021 Immunotherapy with antibodies against PD-1 or PD-L1, either alone or in combination with chemotherapy, has revolutionized treatment paradigms of non-small cell lung cancer (NSCLC) patients without oncogenic driver alterations. These agents, namely immune checkpoint inhibitors (ICIs), have also widely demonstrated a remarkable efficacy in locally ...
Massafra, Marco +8 more
openaire +5 more sources
Management of Febrile Neutropenia - a German Prospective Hospital Cost Analysis in Lymphoproliferative Disorders, Non-Small Cell Lung Cancer, and Primary Breast Cancer [PDF]
, 2011 Background: Febrile neutropenia/leukopenia (FN/FL) is the most frequent dose-limiting toxicity of myelosuppressive chemotherapy, but German data on economic consequences are limited.
Angela Ihbe-Heffinger +19 more
core +1 more source